TG Therapeutics, Inc. last reported quarterly results on Aug 3, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $240.3 million (+70.3% year over year) and diluted EPS of $0.05. It usually reports 34–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 2, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 3, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
240
+70.3%
|
8
-72.4%
|
0.05
-70.6%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
205
+69.6%
|
20
+290.8%
|
0.12
+300.0%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
193
+78.0%
|
23
-1.3%
|
0.14
-0.7%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
162
+92.8%
|
391
+9974.6%
|
2.43
+12050.0%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
141
+92.1%
|
28
+309.8%
|
0.17
+325.0%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
121
+90.4%
|
5
+147.3%
|
0.03
|
|
Mar 3, 2025
62 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
108
+146.0%
|
23
+261.8%
|
0.15
+257.6%
|
|
Nov 4, 2024
35 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
84
-49.4%
|
4
-96.6%
|
0.02
-97.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TGTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1001316
- Former names
- MANHATTAN PHARMACEUTICALS INC (until Apr 27, 2012); ATLANTIC TECHNOLOGY VENTURES INC (until Mar 10, 2003); ATLANTIC PHARMACEUTICALS INC (until Feb 4, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.